Evidence map›Paper›PMID 38987801›Full record

ArticleJournal of nanobiotechnology2024

Yoda1 pretreated BMSC derived exosomes accelerate osteogenesis by activating phospho-ErK signaling via Yoda1-mediated signal transmission.

Xi He, Yanling Liu, Zhongyu Dai, Yu Chen, Wenbin Liu, Honglian Dai, Yihe Hu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. [Research progress on clinical transformation of Piezo1 in osteoarthritis].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Yoda molecules agonize PIEZO2.bioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xi HeDepartment of Orthopedics, The First Affiliated Hospital, Zhejiang University School of medicine, Hangzhou, 310002, China.
Yanling LiuSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Zhongyu DaiDepartment of Orthopedics, The Third Xiangya Hospital, Central South University, Changsha, 410078, China.
Yu ChenDepartment of Orthopedics, The Third Xiangya Hospital, Central South University, Changsha, 410078, China.
Wenbin LiuDepartment of Orthopedics, The Third Xiangya Hospital, Central South University, Changsha, 410078, China. liuwenbin1995@126.com.
Honglian DaiBiomedical Materials and Engineering Research Center of Hubei Province, Wuhan University of Technology, Wuhan, 430070, China. daihonglian@whut.edu.cn.
Yihe HuDepartment of Orthopedics, The First Affiliated Hospital, Zhejiang University School of medicine, Hangzhou, 310002, China. xy_huyh@163.com.

Funding

Natural Science Foundation of China 82302671Program of the National Natural Science Foundation of Hunan Province 2021JJ40989
6 · The paper itself

Abstract

Segmental bone defects, arising from factors such as trauma, tumor resection, and congenital malformations, present significant clinical challenges that often necessitate complex reconstruction strategies. Hydrogels loaded with multiple osteogenesis-promoting components have emerged as promising tools for bone defect repair. While the osteogenic potential of the Piezo1 agonist Yoda1 has been demonstrated previously, its hydrophobic nature poses challenges for effective loading onto hydrogel matrices.In this study, we address this challenge by employing Yoda1-pretreated bone marrow-derived mesenchymal stem cell (BMSCs) exosomes (Exo-Yoda1) alongside exosomes derived from BMSCs (Exo-MSC). Comparatively, Exo-Yoda1-treated BMSCs exhibited enhanced osteogenic capabilities compared to both control groups and Exo-MSC-treated counterparts. Notably, Exo-Yoda1-treated cells demonstrated similar functionality to Yoda1 itself. Transcriptome analysis revealed activation of osteogenesis-associated signaling pathways, indicating the potential transduction of Yoda1-mediated signals such as ErK, a finding validated in this study. Furthermore, we successfully integrated Exo-Yoda1 into gelatin methacryloyl (GelMA)/methacrylated sodium alginate (SAMA)/β-tricalcium phosphate (β-TCP) hydrogels. These Exo-Yoda1-loaded hydrogels demonstrated augmented osteogenesis in subcutaneous ectopic osteogenesis nude mice models and in rat skull bone defect model. In conclusion, our study introduces Exo-Yoda1-loaded GELMA/SAMA/β-TCP hydrogels as a promising approach to promoting osteogenesis. This innovative strategy holds significant promise for future widespread clinical applications in the realm of bone defect reconstruction.

Indexed as

ExosomesHydrogelsMesenchymal Stem CellsOsteogenesisAlginatesAnimalsBone RegenerationCalcium PhosphatesCell DifferentiationCells, CulturedGelatinMaleMAP Kinase Signaling SystemMiceRatsSignal TransductionAlginatesbeta-tricalcium phosphateCalcium PhosphatesGelatinHydrogelsBone defect repairExosomeExtracellular vesiclesHydrogelsOsteogenesisYoda1

Identifiers

PMID38987801
PMCPMC11234696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.